vTv Therapeutics Beheer

Beheer criteriumcontroles 1/4

De CEO vTv Therapeutics is Paul Sekhri, benoemd in Aug2022, heeft een ambtstermijn van 2.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 650.91K, bestaande uit 73.7% salaris en 26.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.19% van de aandelen van het bedrijf, ter waarde € 89.72K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.9 jaar en 0.8 jaar.

Belangrijke informatie

Paul Sekhri

Algemeen directeur

US$650.9k

Totale compensatie

Percentage CEO-salaris	73.7%
Dienstverband CEO	2.3yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	1.9yrs
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Paul Sekhri's beloning veranderd ten opzichte van vTv Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$18m
Jun 30 2024	n/a	n/a	-US$20m
Mar 31 2024	n/a	n/a	-US$21m
Dec 31 2023	US$651k	US$480k	-US$20m
Sep 30 2023	n/a	n/a	-US$22m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$17m
Dec 31 2022	US$2m	US$200k	-US$19m

Compensatie versus markt: De totale vergoeding ($USD 650.91K ) Paul } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 475.63K ).

Compensatie versus inkomsten: De vergoeding van Paul is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Paul Sekhri (66 yo)

2.3yrs

Tenure

US$650,913

Compensatie

Mr. Paul J. Sekhri, M.Sc. is Director of Quercis Pharma AG. Mr. Sekhri is Director at AdhereTech Inc. since February 7, 2024. He serves as Chief Executive Officer, President & Director of vTv Therapeutics...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Sekhri	CEO, President & Chairman of the Board	2.3yrs	US$650.91k	0.19% € 89.7k
Steven Tuch	Executive VP & CFO	1.9yrs	US$465.25k	0.20% € 93.4k
Carmen Valcarce	Chief Scientific Officer & Executive VP	no data	geen gegevens	geen gegevens
Elizabeth Keiley	Executive VP & General Counsel	1.8yrs	geen gegevens	geen gegevens
Richard Nelson	Executive VP of Corporate Development & Director	2.3yrs	US$547.40k	0.42% € 195.2k
Thomas Strack	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

1.9yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 5VT0 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Sekhri	CEO, President & Chairman of the Board	2.3yrs	US$650.91k	0.19% € 89.7k
Richard Nelson	Executive VP of Corporate Development & Director	4yrs	US$547.40k	0.42% € 195.2k
Daniel Spiegelman	Director	less than a year	geen gegevens	geen gegevens
Srinivas Akkaraju	Independent Director	less than a year	geen gegevens	geen gegevens
Anne Phillips	Independent Director	less than a year	geen gegevens	geen gegevens
Raymond Cheong	Lead Independent Director	less than a year	geen gegevens	geen gegevens
Fahed Al-Marzooqi	Independent Director	2.3yrs	US$87.63k	0.024% € 11.2k

0.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 5VT0 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw bestuur.

vTv Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

High number of new and inexperienced directors

vTv Therapeutics Inc., Annual General Meeting, Jun 11, 2024

vTv Therapeutics Inc. Announces Board Changes

Vtv Therapeutics Inc. Announces Resignation of Chandresh Harjivan as Member of the Board of Directors

Vtv Therapeutics Inc. Appoints Thomas Strack, M.D., as Chief Medical Officer

vTv Therapeutics Inc. Appoints Elizabeth Keiley as Executive Vice President and General Counsel

Recent updates

New minor risk - Shareholder dilution

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

High number of new and inexperienced directors

vTv Therapeutics Inc., Annual General Meeting, Jun 11, 2024

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $12.678712 million.

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $12.678712 million.

vTv Therapeutics Inc. Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

vTv Therapeutics Inc. Announces Board Changes

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4.923802 million.

Vtv Therapeutics Inc. Announces Resignation of Chandresh Harjivan as Member of the Board of Directors

vTv Therapeutics Receives Non-Compliance Notice From Nasdaq

Vtv Therapeutics Inc. Appoints Thomas Strack, M.D., as Chief Medical Officer

New major risk - Share price stability

New major risk - Negative shareholders equity

First half 2023 earnings released: US$0.12 loss per share (vs US$0.15 loss in 1H 2022)

Nasdaq Approves vTv Therapeutics' Request to Extend the Period to Regain Compliance with the Minimum Bid Requirement Until December 18, 2023

First quarter 2023 earnings released: US$0.055 loss per share (vs US$0.10 loss in 1Q 2022)

vTv Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.26 loss per share (vs US$0.21 loss in FY 2021)

vTv Therapeutics Inc. Appoints Elizabeth Keiley as Executive Vice President and General Counsel

vTv Therapeutics Receives a Letter from NASDAQ Regarding Minimum Bid Price

vTv Therapeutics Inc. Appoints Steven Tuch as Chief Financial Officer

Third quarter 2022 earnings released: US$0.053 loss per share (vs US$0.018 loss in 3Q 2021)

High number of new directors

Third quarter 2022 earnings released: US$0.053 loss per share (vs US$0.018 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.045 loss per share (vs US$0.01 loss in 2Q 2021)

vTv Therapeutics Inc. Appoints Jonathan Isaacsohn as Member and Chair of the Board

High number of new directors

vTv Therapeutics Inc. Announces CEO Changes

Jon Isaacsohn to Join the vTv Therapeutics Inc. Board of Directors

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

vTv Therapeutics Inc. announced that it expects to receive $24.999762 million in funding from G42 Investments Ai Holding Rsc Ltd

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.075 loss in 1Q 2021)

vTv Therapeutics Inc., Annual General Meeting, Jun 01, 2022

Robin E. Abrams Resigns as Executive Chairperson of the Board of Directors of vTv Therapeutics Inc

vTv Therapeutics Inc. Announces Not to Stand for Re-Election of Noel Spiegel as Director and Chair of the Audit Committee of the Board

Full year 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in FY 2020)

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Inc. Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

vTv Therapeutics Inc.(NasdaqCM:VTVT) dropped from Russell 3000E Index

First quarter 2021 earnings released: US$0.075 loss per share (vs US$0.11 loss in 1Q 2020)

vTv Therapeutics Inc. Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes

Director recently bought €142k worth of stock

Full year 2020 earnings released: US$0.18 loss per share (vs US$0.59 loss in FY 2019)

Revenue beats expectations

vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes

vTv Therapeutics Inc. Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Announces Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes

New 90-day high: €1.83

vTv Therapeutics Inc. Appoints Rich Nelson as A Member of the Board

Revenue in line with expectations

vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study

Edward P. Taibi Resigns from the Board of Directors of vTv Therapeutics, Inc

vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd